Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients

Inclusion Criteria:

* Age \>= 75
* Histologically proven prostate adenocarcinoma
* Metastatic disease, not pre-treated with chemotherapy refractory to castration
* Hormone refractory prostate cancer is defined as follows:

  * Patients with documented testosterone castration (\<0.50 ng / ml)
  * Patient who received prior hormonal therapy (either orchidectomy or Luteinizing hormone-releasing hormone (LHRH) agonist alone or combined with an anti-androgen)
  * Patients should continue primary androgen suppression by LHRH agonist (in case of non-surgical castration)
  * For patients treated with anti-androgens prior to inclusion, a wash-out period is required (4 weeks for flutamide and nilutamide, 6 weeks for other products) as well as measured progression after anti-androgen discontinuation.
* Progressive disease under hormonotherapy, with progression defined by

Increase of PSA level (two consecutive increases of PSA compared to baseline with a minimum of one week between both measurements)

OR emergence of a new lesion

OR measurable progressive disease (increase of a previous measurable lesion \>= 25% in cross section)

OR progressive bone metastases (defined only by the appearance of a new lesion on bone scan)

OR progressive symptoms (defined as cancer pain Grade 2 according to the NCI-CTC V4.0, despite level 2 analgesics intake).

* Patients of Groups 2 and 3 \[ "vulnerable" and "frail"\] of SIOG classification
* WHO Performance Status (PS) \>= 3
* PSA \>= 5 ng / ml
* Neutrophils \>= 2.109 /L
* Platelets \>= 100.109/L
* Haemoglobin ≥ 9 g/dl
* Bilirubin and SGOT / SGPT \<1.5 x ULN (\<= 2.5 x ULN if hepatic metastasis)
* creatinine \<= 2.5 x ULN
* In case of previous palliative or analgesic radiotherapy, a minimum of 14 days must have elapsed between end of radiotherapy and inclusion into the study
* Previous treatment with bisphosphonates should be continued without change during the study treatment and can not be initiated either within 28 days prior to study entry or during the study
* Signed informed consent by patients, according to local regulations

Exclusion Criteria:

* "healthy" or "terminal illness" Groups according to the recommendations of International Society of Geriatric Oncology (SIOG)
* Concomitant or previous malignancy within 5 years prior the study (except basal or squamous in situ cell skin carcinoma)
* Presence of brain metastasis symptoms
* Prior treatment by intravenous radiopharmaceutical agent (e.g. Strontium 89, Samarium lexidronam) within 2 months before study entry
* Initiation of a bisphosphonate therapy within 28 days prior to randomisation
* Any concomitant anticancer treatment (radiotherapy, radiopharmaceutical agent, chemotherapy)
* Patients with uncontrolled infection
* Patients with peripheral neuropathy of grade\> 1
* Patients medically unstable (e.g. unstable diabetes, uncontrolled hypertension or decompensated heart failure or myocardial infarct within 3 months)
* Gastro duodenal active ulcer
* Hypersensitivity to study drugs
* Treatment with any experimental drug within 30 days prior to or during the study
* Psychological, familial, sociological or geographical location conditions which do not allow medical monitoring and compliance with study protocol.
* Patients protected by the law or patients placed under protective supervision of adults